- Home
- SEED vs LYRA Comparison
SEED vs LYRA Comparison
Compare SEED & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEED
- LYRA
- Stock Information
- Founded
- SEED 1997
- LYRA 2005
- Country
- SEED China
- LYRA United States
- Employees
- SEED N/A
- LYRA N/A
- Industry
- SEED Farming/Seeds/Milling
- LYRA Medical/Dental Instruments
- Sector
- SEED Consumer Staples
- LYRA Health Care
- Exchange
- SEED Nasdaq
- LYRA Nasdaq
- Market Cap
- SEED 18.3M
- LYRA 18.0M
- IPO Year
- SEED N/A
- LYRA 2020
- Fundamental
- Price
- SEED $2.30
- LYRA $0.17
- Analyst Decision
- SEED
- LYRA Buy
- Analyst Count
- SEED 0
- LYRA 5
- Target Price
- SEED N/A
- LYRA $4.50
- AVG Volume (30 Days)
- SEED 22.4K
- LYRA 2.2M
- Earning Date
- SEED 11-29-2024
- LYRA 11-12-2024
- Dividend Yield
- SEED N/A
- LYRA N/A
- EPS Growth
- SEED N/A
- LYRA N/A
- EPS
- SEED 1.21
- LYRA N/A
- Revenue
- SEED $16,516,031.00
- LYRA $1,471,000.00
- Revenue This Year
- SEED N/A
- LYRA $13.99
- Revenue Next Year
- SEED N/A
- LYRA N/A
- P/E Ratio
- SEED $1.90
- LYRA N/A
- Revenue Growth
- SEED 64.93
- LYRA 3.37
- 52 Week Low
- SEED $1.37
- LYRA $0.17
- 52 Week High
- SEED $6.38
- LYRA $6.79
- Technical
- Relative Strength Index (RSI)
- SEED 34.00
- LYRA 30.70
- Support Level
- SEED $2.49
- LYRA $0.26
- Resistance Level
- SEED $2.78
- LYRA $0.28
- Average True Range (ATR)
- SEED 0.22
- LYRA 0.02
- MACD
- SEED -0.03
- LYRA -0.01
- Stochastic Oscillator
- SEED 25.00
- LYRA 1.69
About SEED Origin Agritech Limited
Origin Agritech Ltd is a Chinese agricultural technology company. In crop seed biotechnologies, the company's phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China's Ministry of Agriculture. Origin has established a robust biotechnology seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.